356 related articles for article (PubMed ID: 7535843)
61. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
[TBL] [Abstract][Full Text] [Related]
62. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
[TBL] [Abstract][Full Text] [Related]
63. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
[TBL] [Abstract][Full Text] [Related]
64. [Low-dose granulocyte colony-stimulating factor combined with granulocyte-macrophage colony-stimulating factor for mobilizing peripheral CD34+ hematopoietic progenitor cells].
Meng FY; Xu B; Sun J; Yang Y; Niu JN
Di Yi Jun Yi Da Xue Xue Bao; 2004 Sep; 24(9):1051-2. PubMed ID: 15447861
[TBL] [Abstract][Full Text] [Related]
65. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.
Petit J; Boqué C; Cancelas JA; Sarrà J; Muñoz J; Garcia J; Grañena A
Leuk Lymphoma; 1999 Jun; 34(1-2):119-27. PubMed ID: 10350339
[TBL] [Abstract][Full Text] [Related]
66. Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma.
Jonkhoff AR; De Kreuk AM; Franschman G; Van Der Lelie J; Schuurhuis GJ; Dräger AM; Zweegman S; Huijgens PC; Ossenkoppele GJ
Br J Haematol; 2002 Jul; 118(1):90-100. PubMed ID: 12100131
[TBL] [Abstract][Full Text] [Related]
67. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
Ossenkoppele GJ; Schuurhuis GJ; Jonkhoff AR; Dräger AM; Westra G; Oberink JW; Legdeur MC; de Kreuk AM; Zweegman S; Huijgens PC
Bone Marrow Transplant; 1996 Aug; 18(2):427-31. PubMed ID: 8864457
[TBL] [Abstract][Full Text] [Related]
68. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
Devereaux S; Linch DC; Gribben JG; McMillan A; Patterson K; Goldstone AH
Bone Marrow Transplant; 1989 Jan; 4(1):49-54. PubMed ID: 2647187
[TBL] [Abstract][Full Text] [Related]
69. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
[TBL] [Abstract][Full Text] [Related]
70. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
71. Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Damiani D; Grimaz S; Infanti L; Sperotto A; Silvestri F; Geromin A; Cerno M; Savignano C; Michieli M; Skert C; Fanin R; Baccarani M
Bone Marrow Transplant; 1999 Oct; 24(7):757-61. PubMed ID: 10516679
[TBL] [Abstract][Full Text] [Related]
72. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
73. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
Ricca I; Compagno M; Ladetto M; Rocci A; Dell'Aquila M; Omedè P; De Marco F; D'Antico S; Caracciolo D; Ferrero D; Carlo-Stella C; Tarella C
Leukemia; 2005 Apr; 19(4):644-51. PubMed ID: 15716989
[TBL] [Abstract][Full Text] [Related]
74. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
75. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Jantunen E; Kuittinen T; Nousiainen T
Leuk Lymphoma; 2003 Jul; 44(7):1151-8. PubMed ID: 12916867
[TBL] [Abstract][Full Text] [Related]
76. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
[TBL] [Abstract][Full Text] [Related]
77. Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor.
Haas R; Möhle R; Murea S; Goldschmidt H; Pförsich M; Witt B; Hunstein W
J Hematother; 1994; 3(4):323-30. PubMed ID: 7537608
[TBL] [Abstract][Full Text] [Related]
78. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
79. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
80. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
